<internation circulation>:
Dr. Holmes， What is your opinion about the risk versus benefit in combination therapy between interventions coagulants and anti-platelet drugs? 

Holmes:
I think the more important issue is: what is the risk / benefit ratio of those patients who are going to need oral anti-coagulants in addition to duel anti-platelet agents; that’s the crucial question at the present time.   Given that oral anti-coagulants are given for a wide variety of clinical situations， such as arterial fibrillation， stoke prevention， etc.  And yet in that same patient population they’re getting drug eluding stents.  So they then get dual anti-platelet therapy.   So they then wind-up being on aspirin， Clopidogrel  and Warfarin; its that group that is the most problematic because their incidence of bleeding is increased.